Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13D/A

Medicus Pharma Ltd.

MDCXNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 17, 2026Accepted Nov 17, 2026, 5:21 PM ESTFiling CIK 1997296Accession 0000950142-26-003112
Share

Structured filing — SCHEDULE 13D/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Medicus Pharma Ltd.
Company CIK
0001997296
Street
300 Conshohocken State Road
Street (continued)
Suite 200
City
West Conshohocken
State / country code
PA
Postal code
19428

Statement details

Amendment number
1
Security class
Common shares, no par value
Event date
11/13/2026
Previously filed indication
false

Authorized notification person 1

Name
Dr. Raza Bokhari
Phone
610-540-7515
Street
300 Conshohocken State Road
Street (continued)
Suite 200
City
West Conshohocken
State / country code
PA
Postal code
19428

Reporting person 1

Name
BOKHARI, RAZA
Reporting person CIK
0001660525
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN
Source of funds code
PF · OO
Legal proceedings indication
N
Aggregate amount owned
538,233.00
Percent of class
19.1
Sole voting power
86,424.00
Shared voting power
451,909.00
Sole dispositive power
86,424.00
Shared dispositive power
451,909.00
Aggregate excludes certain shares
N
Comments
Includes (i) 27,500 common shares underlying stock options held by Dr. Raza Bokhari that are currently exercisable or will become exercisable within 60 days of the date hereof, (ii) 58,924 common shares held directly by Dr. Raza Bokhari and (iii) 451,909 common shares held by RBx Capital, LP, an entity controlled by Dr. Raza Bokhari (including the 436,046 common shares acquired by RBx Capital, LP in the Private Placement (as defined in Item 3)). Dr. Raza Bokhari may be deemed the beneficial owner of the securities held by RBx Capital, LP. Dr. Raza Bokhari disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Reporting person 2

Name
RBx Capital, LP
No reporting person CIK indication
Y
Citizenship / organization
DE
Reporting person type
PN
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
451,909.00
Percent of class
16.2
Sole voting power
0.00
Shared voting power
451,909.00
Sole dispositive power
0.00
Shared dispositive power
451,909.00
Aggregate excludes certain shares
N

Item 1

Issuer

Medicus Pharma Ltd.

Security title

Common shares, no par value

Principal address

Comment

This Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the statement on Schedule 13D filed with the SEC on September 14, 2026 (the "Original Schedule 13D") by the Reporting Persons with respect to the common shares, no par value, of Medicus Pharma Ltd. (the "Issuer"). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Original Schedule 13D. Capitalized terms used but not defined herein have the meanings ascribed to them in the Original Schedule 13D.

Item 3

Source of funds

Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows: On November 13, 2026, RBx Capital, LP, an entity controlled by Dr. Raza Bokhari, entered into a subscription agreement with the Issuer, pursuant to which RBx Capital, LP agreed to purchase 436,046 common shares (the "Private Placement Shares") in a private placement by the Issuer (the "Private Placement") at a purchase price of $1.72 per common share, for an aggregate purchase price of $749,999.12. The Private Placement Shares were acquired using the working capital of RBx Capital, LP.

Item 4

Purpose of transaction

Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 3 of this Amendment No. 1 is incorporated herein by reference. RBx Capital, LP acquired the Private Placement Shares for general investment purposes. Except as set forth in this Item 4, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the transactions or other matters specified in clauses (a) through (j) of Item 4 of Schedule 13D, although each Reporting Person reserves the right to formulate and pursue any such plans or proposals in the future, and to change its intentions with respect to any and all of the matters referred to in this Item 4.

Item 5

Number of shares

See Rows (7), (8), (9) and (10) of each Reporting Person's cover page.

Transactions

Except as described in Items 3 and 4 above of this Amendment No. 1, neither Reporting Person effected any transaction in the common shares during the 60 days preceding the date of the event that requires the filing of this statement.

Other persons with an interest

No person other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the common shares reported herein.

Date ownership ceased to exceed 5%

Not applicable.

Percentage of class

Item 5 of the Original Schedule 13D is hereby amended and restated in their entirety as follows: See Rows (11) and (13) of each Reporting Person's cover page. The percentages reported herein for RBx Capital, LP are calculated based on 2,788,106 common shares issued and outstanding as of November 16, 2026, as confirmed by the Issuer's transfer agent on such date. The percentages reported herein for Dr. Raza Bokhari are calculated based on 2,788,106 common shares issued and outstanding as of November 16, 2026, as confirmed by the Issuer's transfer agent on such date, plus 27,500 common shares underlying stock options held by Dr. Raza Bokhari that are currently exercisable or will become exercisable within 60 days of the date hereof.

Item 6

Contracts and arrangements

Item 6 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 3 of this Amendment No. 1 is incorporated herein by reference.

Signature 1

Reporting person
BOKHARI, RAZA
Signed
/s/ Raza Bokhari
Title
Dr. Raza Bokhari
Date
11/17/2026

Signature 2

Reporting person
RBx Capital, LP
Signed
/s/ Raza Bokhari
Title
Dr. Raza Bokhari, Managing Partner
Date
11/17/2026

Company context

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and  accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are  developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Current securities

Recent company filings

  1. 4 filingNov 17, 2026
  2. 4 filingNov 17, 2026
  3. 4 filingNov 17, 2026
  4. 424B3 filingNov 16, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Other EventsNov 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.